Search the Newsreel

Conmed’s AirSeal Robotic Solution OK’ed for Intuitive da Vinci 5 Hex Cannula

Conmed Corp. has received expanded indication for its AirSeal robotic solution, allowing it to be used with Intuitive’s 8 mm hex cannulas for the da Vinci 5 platform. This new approval builds on its existing compatibility with Intuitive’s da Vinci 8mm round cannulas, offering …

CONMED expands AirSeal compatibility to da Vinci 5 platform

CONMED Corporation (NYSE:CNMD) announced an expanded indication for its AirSeal Robotic Solution, making it compatible with Intuitive's 8 mm hex cannulas used in the da Vinci 5 platform. This expansion means the AirSeal solution can now be used across all of Intuitive's da Vinci …

CONMED (CNMD) to Announce Quarterly Earnings on Wednesday

Allspring Global Investments Holdings LLC Increases Holdings in CONMED Corporation $CNMD

Allspring Global Investments Holdings LLC significantly increased its stake in CONMED Corporation (NYSE:CNMD) by 39.9% in the first quarter, bringing its total holding to 582,733 shares valued at approximately $20.7 million. This increase comes despite several analysts maintaining a cautious outlook on CONMED, with …

In 40 Robotic Prostatectomies, AirSeal Had Fewer Nociceptive Events per Hour

CONMED Corporation announced that its AirSeal® Insufflation System demonstrated superior performance over Stryker's PneumoClear Insufflator in a randomized controlled clinical trial involving 40 robotic prostatectomy patients. The trial found that the AirSeal arm had significantly fewer intraoperative nociceptive events per hour, shorter procedure and …

CONMED (NYSE:CNMD) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded CONMED (NYSE:CNMD) stock from "hold" to "buy," despite a mixed outlook from other analysts who largely rate it as "Reduce" with an average target price of $38.80. This upgrade comes after CONMED surpassed quarterly earnings and revenue estimates, reporting …

CNMD5600366 Bond Profile — Key Metrics

This article provides the key metrics for the CONMED Corporation's 2.25% bond, CNMD5600366, maturing on June 15, 2027. It details the issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. Additionally, it offers a brief company profile of CONMED …

CONMED files Form 3 for EVP, CFO John Gallagher`

CONMED has filed a Form 3 for John E. Gallagher, officially naming him as Executive Vice President and Chief Financial Officer, effective July 15, 2026. This news brief, generated by Public Technologies (PUBT) using AI, is based on the original content published by CONMED …

Form 4 CONMED Corporation For: 17 July By Investing.com

This article reports on a Form 4 filing for CONMED Corporation (NYSE: CNMD) made on July 17. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The brief notice from Investing.com indicates that such a filing was …

CONMED Corp (NYSE: CNMD) grants CFO stock options and RSUs

CONMED Corp (NYSE: CNMD) has granted its Executive Vice President and CFO, John E. Gallagher, stock options and Restricted Stock Units (RSUs) as part of the company's 2025 Long-Term Incentive Plan. Gallagher received 30,536 stock options with an exercise price of $42.79 per share …

ETFs Investing in CONMED Corporation Stocks

This article lists numerous Exchange Traded Funds (ETFs) that hold shares of CONMED Corporation. It provides a detailed table with each ETF's market value, weight of CONMED stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and …

Understanding Momentum Shifts in (CNMD)

This article analyzes momentum shifts for Conmed Corp. (CNMD) using AI models, outlining near- and mid-term strong sentiment but a weak long-term outlook. It provides specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and …

CONMED schedules Q2 results call for July 29 after market close

Why Is Conmed (CNMD) Down 3.1% Since Last Earnings Report?

5 Revealing Analyst Questions From CONMED’s Q1 Earnings Call

Does CONMED (CNMD) Refocusing Away From Gastroenterology Clarify Its Long-Term Surgical Growth Story?

CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up